Over the Next Decade, the Malignant Melanoma Drug Market Will Increase More Than Seven-Fold to $1.5 Billion in 2020

Drug Approvals—Most Notably the Launches of Yervoy and Zelboraf—Will Drive Robust Market Growth, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma drug market will increase more than seven-fold over the next decade, growing from $210 million in 2010 to $1.5 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although this space had been constrained by a dearth of novel therapies in recent years, robust market growth will be driven by highly anticipated drug approvals—most notably Bristol-Myers Squibb’s Yervoy and Roche/Genentech/Chugai/Daiichi Sankyo’s Zelboraf—which have created significant changes in the treatment of malignant melanoma.

The findings from the Pharmacor topic entitled Malignant Melanoma reveal that although Yervoy’s sales have been robust since its recent launch in the United States, the market entry of the BRAF kinase inhibitor Zelboraf will propel it to quickly replace Yervoy as the agent of choice for patients with the BRAF gene mutation. As a result, Zelboraf will relegate Yervoy to an efficacious and welcomed second-line option for this patient population.

The findings also reveal that interviewed experts indicate that they are eagerly awaiting the results of the ongoing clinical trial combining GlaxoSmithKline’s BRAF inhibitor dabrafenib with the company’s MEK inhibitor trametinib, an approach they are hopeful could delay the development of resistance to BRAF inhibitors. However, the combination’s efficacy, in particular the duration of response, will need to be convincingly superior for it to substantially challenge Zelboraf.

Despite the availability of new agents for malignant melanoma, substantial unmet need remains, including for the large, resectable disease population.

“Significant commercial reward awaits the developer of a therapy that is at least as effective as but safer and more tolerable than high dose interferon-alpha—Merck’s Intron A—or PEG-interferon-alpha—Merck’s Sylatron—in the adjuvant setting for resectable malignant melanoma,” said Decision Resources Analyst Rachel Webster, D.Phil. “Yervoy is currently being investigated in two Phase III trials in this setting, and vaccines continue to attract interest from developers.”

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.